C. Curtin

发表

Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men

K. Wesnes, F. Brunner‐Ferber, C. Kleinbloesem, 1996, Clinical pharmacology and therapeutics.

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

P. Rothenberg, E. Wajs, S. Weiner, 2014, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment

D. Heald, L. Ford, C. Curtin, 2014, Epilepsy Research.

Bioequivalence of Canagliflozin/Metformin Immediate Release Fixed-Dose Combination Tablets Compared with Concomitant Administration of Single Components of Canagliflozin and Metformin in Healthy Fed Participants

E. Wajs, S. Weiner, J. Murphy, 2014 .

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.

Xia Chen, P. Hu, S. Weiner, 2015, Clinical therapeutics.

Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-β-Cyclodextrin in Infants, Children, and Adolescents

R. Kauffman, G. Kearns, R. Jacobs, 2007, Antimicrobial Agents and Chemotherapy.

Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl- (cid:2) -Cyclodextrin in Infants, Children, and Adolescents (cid:1)

R. Kauffman, G. Kearns, R. Jacobs, 2007 .

Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.

R. Kauffman, G. Kearns, R. Jacobs, 2007, Antimicrobial agents and chemotherapy.

Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin

J. Natarajan, R. R. Williams, C. Fowler, 1997, Journal of clinical pharmacology.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

S. Chien, A. Chow, J. Natarajan, 1997, Antimicrobial agents and chemotherapy.

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

P. Rothenberg, J. Murphy, M. Gutierrez, 2013, Journal of clinical pharmacology.

Pharmacokinetic Interactions of Topiramate

R. Twyman, M. Bialer, S. Schwabe, 2004, Clinical pharmacokinetics.

Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic Patients

M. Bialer, R. Sachdeo, L. Roskos, 2002, Epilepsia.

Pharmacokinetic interactions between topiramate and pioglitazone and metformin

D. Heald, L. Ford, C. Curtin, 2014, Epilepsy Research.

Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol

D. Heald, L. Ford, C. Curtin, 2014, Clinical pharmacology in drug development.

Lack of Effect of a High‐Fat Meal on the Bioavailability of 17β‐Estradiol/Norgestimate in Healthy Postmenopausal Women

J. Natarajan, F. Wong, C. Curtin, 2000, Journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

E. Wajs, J. Murphy, H. Stieltjes, 2015, International journal of clinical pharmacology and therapeutics.

Bioequivalence of a Newly Developed 17β-Estradiol Tablet versus an Identical Reference Formulation

J. Natarajan, F. Wong, L. Gisclon, 2000, Arzneimittelforschung.

The pharmacokinetics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis

S. Chien, C. Curtin, M. Corrado, 1996 .

An Open-Label Drug–Drug Interaction Study of the Steady-State Pharmacokinetics of Topiramate and Glyburide in Patients with Type 2 Diabetes Mellitus

D. Heald, L. Ford, C. Curtin, 2013, Clinical Drug Investigation.

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

William Smith, E. Wajs, T. Marbury, 2015, Clinical therapeutics.

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.

E. Wajs, H. Stieltjes, D. Devineni, 2016, Clinical therapeutics.